Order Article Reprints

Pugliese N, Picardi M, Della Pepa R, Giordano C, Muriano F, Leone A, Delle Cave G, D’Ambrosio A, Marafioti V, Rascato MG, et al. Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up. Cancers. 2021; 13(8):1760. https://doi.org/10.3390/cancers13081760

Pugliese, Novella, Marco Picardi, Roberta Della Pepa, Claudia Giordano, Francesco Muriano, Aldo Leone, Giuseppe Delle Cave, Alessandro D’Ambrosio, Violetta Marafioti, Maria Gabriella Rascato, and et al. 2021. "Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up" Cancers 13, no. 8: 1760. https://doi.org/10.3390/cancers13081760

Pugliese, N., Picardi, M., Della Pepa, R., Giordano, C., Muriano, F., Leone, A., Delle Cave, G., D’Ambrosio, A., Marafioti, V., Rascato, M. G., Russo, D., Mascolo, M., & Pane, F. (2021). Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up. Cancers, 13(8), 1760. https://doi.org/10.3390/cancers13081760